| Hans-Günter Meyer-Thompson | Fentanyl
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Rollman JE, Heyward J, Olson L, Lurie P, Sharfstein J, Alexander GC.
JAMA. 2019;321(7):676–685. doi:10.1001/jama.2019.0235
Abstract
https://jamanetwork.com/journals/jama/article-abstract/2725233